

[Drug Injury Watch: Diabetes Drugs Like Januvia Linked To Severe Joint Pain Side Effects](#)

(Posted by Tom Lamb at www.DrugInjuryWatch.com on August 28, 2015)

The "FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain" document which was issued on August 28, 2015 announced that The FDA found drug adverse event reports of arthralgia, or severe pain in one or more joints, associated with the use a class of diabetes drugs -- dipeptidyl peptidase-4 (DPP-4) inhibitors -- that includes Januvia, Onglyza, Tradjenta, and Nesina.

According to the FDA, patients started having symptoms of the new side effect from one day to years after they started taking Januvia, Onglyza, Tradjenta, Nesina or one of the "combination" DPP-4 inhibitors, *e.g.*, Janumet (sitagliptin and metformin).

In more detail, the FDA reported that after the DPP-4 inhibitor medicine was discontinued, the patients' symptoms were usually relieved within less than a month of stopping the subject drug. Furthermore, some patients developed severe joint pain again when they restarted the same medicine or another DPP-4 inhibitor.

This last fact provides some substantiation for linking this severe joint pain side effect with Januvia, Onglyza, Tradjenta, Nesina, and the other drugs in this DPP-4 inhibitors class.

According to this FDA Drug Safety Communication, Januvia was implicated most often for this severe joint pain side effect, followed by Onglyza.

Finally, due to this drug safety development, the FDA has mandated that the respective drug companies add a new Warning and Precaution about this risk to the drug labels of all medicines in this dipeptidyl peptidase-4 (DPP-4) inhibitors class.

[\[Read this article in full at original source\]](#)

Earlier articles by attorney Tom Lamb on the [Side Effects Blog](#):

- [Despite Benefits Of Jardiance, There Are Still Safety Concerns](#)
- [New Blood-Thinner Savaysa Has No Antidote To Reverse Acute Bleeding](#)
- [Gilenya PML Warning Label Change Made In August 2015](#)
- [Another Blood-Clots Warning Label Change For YAZ Coming?](#)
- [FDA May Require New Onglyza Drug Label For Warning About Heart Failure](#)

Attorney [Tom Lamb](#) represents people in personal injury and wrongful death cases involving unsafe prescription drugs or medication errors. The above article was posted originally on his blog, **Drug Injury Watch** – with live links and readers' Comments.
<http://www.DrugInjuryWatch.com>